Pieris AG has achieved a preclinical milestone within its R&D collaboration with Sanofi (EURONEXT: SAN and NYSE: SNY), triggering an undisclosed payment, the company announced today. The milestone relates to the generation of sub-nanomolar Anticalins against multiple targets within a single therapeutic program, forming the building blocks for a multispecific program.